Ezose Sciences Inc. announced that it has entered a research agreement with Kyowa Hakko Kirin Co., Ltd. to collaborate on glycomics studies using Ezose's proprietary GlycanMap(R) technology platform. Under terms of the research agreement, Kyowa Hakko Kirin will fund several glycan-biomarker and other discovery projects, with an option for further research and development. Other details of the agreement were not disclosed.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,100 JPY | -0.23% | +5.86% | +30.80% |
03/07 | Kyowa Kirin Buys Back Shares | MT |
02/07 | Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024. | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.80% | 10.39B | |
+6.87% | 72.01B | |
+40.84% | 5.26B | |
-18.53% | 4.64B | |
+12.65% | 3.7B | |
+27.58% | 2.3B | |
-39.96% | 1.8B | |
-45.87% | 1.7B | |
-0.50% | 1.64B | |
0.00% | 1.58B |
- Stock Market
- Equities
- 4151 Stock
- News Kyowa Kirin Co. Ltd.
- Ezose Sciences Inc. Enters Glycomics Research Agreement with Kyowa Hakko Kirin Co., Ltd